DrugPatentWatch Database Preview
XOLAIR Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for Tradename: XOLAIR
| Patents: | 107 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for XOLAIR |
Recent Clinical Trials for XOLAIR
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of California, Davis | Phase 3 |
| Thermo Fisher Scientific | Phase 4 |
| Carsten Bindslev-Jensen | Phase 4 |
Pharmacology for XOLAIR
| Mechanism of Action | IgE-directed Antibody Interactions |
| Physiological Effect | Decreased IgE Activity |
Patent Text Search: US Patents for XOLAIR
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | ATOPIX THERAPEUTICS LIMITED (London, GB) | 2034-05-02 | RX | search | |
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | Knopp Biosciences LLC (Pittsburgh, PA) | 2033-08-13 | RX | search | |
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | AbbVie Inc. (North Chicago, IL) | 2026-09-08 | RX | search | |
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | ALEXION PHARMACEUTICALS, INC. (New Haven, CT) | 2024-12-29 | RX | search | |
| Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | Adventist Health System/Sunbelt Inc. (Altamonte Springs, FL) | 2034-11-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for XOLAIR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 20071717 | Start Trial |
| Japan | 5366407 | Start Trial |
| China | 101597209 | Start Trial |
| Spain | 2661032 | Start Trial |
| European Patent Office | 2075066 | Start Trial |
| China | 107011861 | Start Trial |
| European Patent Office | 1853313 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XOLAIR
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122015000061 | Germany | Start Trial | PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| 92780 | Luxembourg | Start Trial | PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826 |
| 122016000049 | Germany | Start Trial | PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621 |
| CA 2015 00043 | Denmark | Start Trial | PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826 |
| 300753 | Netherlands | Start Trial | PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| CA 2016 00031 | Denmark | Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 |
| 300822 | Netherlands | Start Trial | PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
